SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets quarterly earnings miss, softer Search and advertising growth, and heavy AI infrastructure spending that pushed free cash flow negative overshadowed strong Google Cloud growth and drove a sharp selloff. Traders are split between calling the drop an overreaction and buying opportunity and warning that search pressure and spending intensity could weigh on returns.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances announcement that it will present positive Phase 2 lifileucel results in previously treated metastatic lung cancer has driven attention, with traders focused on whether the TIL therapy can expand beyond melanoma. The community is largely bullish, though some caution that the detailed results and regulatory implications remain uncertain; short-squeeze and buyout talk is speculative.

Alphabet Inc - Ordinary Shares - Class C

Alphabets earnings miss and heavy AI infrastructure spending, which weighed on cash flow, are driving concern about whether future returns will justify the investment, despite strong Google Cloud growth. Traders are divided between viewing the selloff as an overreaction and warning that spending and competition in search could pressure the business further.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows quarterly earnings miss and softer outlook for near-term contracted-revenue growth overshadowed revenue growth and a higher AI target, driving a steep selloff. Traders are divided between viewing the drop as an overreaction and worrying about slowing growth, valuation, and AI disruption.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Reports that Marvell is in advanced talks to acquire optical-component maker Lumentum have fueled discussion, though no deal is final. Traders see potential strategic benefits for AI data-center optics but debate whether financing could bring substantial dilution or debt, contributing to volatile reactions.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts quarterly results beat expectations, with accelerating Azure growth and capital spending below forecasts lifting enthusiasm for its AI and cloud business. Traders largely welcomed the report but debated whether the initial after-hours rally would hold, with some pointing to ongoing AI investment and free-cash-flow concerns.

Fortinet, Inc. provides cybersecurity solutions to a variety of businesses, such as enterprises, communication service providers, government organizations, and small to medium-sized businesses. Its product portfolio includes network security, secure access service edge, enterprise networking, security operations, application security, and operational technology. The company was founded by Ken Xie and Michael Xie in November 2000 and is headquartered in Sunnyvale, CA.

Fortinet Inc

Fortinets quarterly results triggered a sharp selloff despite beating headline estimates and raising its overall outlook; traders focused on slowing product growth, weaker service-revenue guidance, and margin pressure, especially after a steep run-up in the shares. The community is split between viewing the drop as an overreaction and seeing it as a valuation reset, with weakness also weighing on other cybersecurity stocks.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

Upbits reported JASMY delisting or trading-pair removal, including a withdrawal deadline discussed by traders, is fueling concern as the token falls. The community is divided between seeing the exchange action as a serious negative signal and dismissing it as limited or manageable, with some holders buying the dip.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum is drawing attention after reports that Marvell is in advanced talks to acquire it, a potential deal that traders see as strategically attractive for AI data-center optics but question over financing, dilution, and whether an agreement will materialize. The reported takeover sparked a sharp move in LITE, followed by volatile trading and debate over whether the gains will hold.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

BlackRocks reported increase in its TGTX stake to 13.8% is drawing attention, with bullish traders viewing the filing as institutional accumulation alongside BRIUMVIs sales momentum. The community is also watching for price follow-through; buyout and short-squeeze claims remain speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ANIP 🏥 

ANI Pharmaceuticals, Inc. announced positive Phase 4 SYNCHRONICITY trial results showing statistically significant improvements in BCVA letter score and CST at 6 months, maintained at 24 months in patients with chronic NIU-PS. 

Actionable market event

Mark Hogue

2525Gus

T Lindsay

Gustavo R Gurovich

StockTwits Web

ANI Pharmaceuticals Inc

 🏥 

ANI Pharmaceuticals, Inc. announced positive Phase 4 SYNCHRONICITY trial results showing statistically significant improvements in BCVA letter score and CST at 6 months, maintained at 24 months in patients with chronic NIU-PS. 

Actionable market event

Rayvio | Market News Filter

@Rayvio_News_Filter  
Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline in CST with statistical significance1 at 6 months, and these changes were maintained at 24 months (a key secondary endpoint) 
 
The most common adverse events reported were consistent with prior trials of fluocinolone acetonide intravitreal implant 0.18 mg 
 
Study evaluated patients with chronic NIU-PS in the U.S.; most patients in the study were treated by retina specialists

  
Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline in CST with statistical significance1 at 6 months, and these changes were maintained at 24 months (a key secondary endpoint) 
 
The most common adverse events reported were consistent with prior trials of fluocinolone acetonide intravitreal implant 0.18 mg 
 
Study evaluated patients with chronic NIU-PS in the U.S.; most patients in the study were treated by retina specialists